Neuronetics® Celebrates 500,000 Treatment Milestone for Greenbrook® TMS
“Our mission at
Depression currently impacts more than 13.3 million adults in the U.S.,1,2,3 but many do not seek treatment or are not helped by antidepressant medications. NeuroStar Advanced Therapy is a non-drug, non-invasive treatment for adults with Major Depressive Disorder (MDD) that uses magnetic pulses to stimulate areas of the brain that are underactive in depression.4,5 Patients undergoing NeuroStar treatments are able to drive to and from each treatment session.
“A milestone of this magnitude is a true testament to what can happen when we work together to expand access to proven, non-drug treatment options,” said
Since receiving FDA clearance in 2008 as a safe and effective option for adult patients with Major Depressive Disorder (MDD), NeuroStar has been a trailblazer in treatment of depression and is the number one choice of TMS doctors. More than three million NeuroStar treatments have been delivered across nearly 900 practice locations in the
About Neuronetics
About NeuroStar® Advanced Therapy
NeuroStar® Advanced Therapy is the market leader in transcranial magnetic stimulation (TMS), a non-invasive form of neuromodulation, and the #1 choice of TMS doctors for patients with Major Depressive Disorder (MDD). Widely available across the United States, NeuroStar is reimbursed by most commercial and government health plans, including Medicare and Tricare.
In the U.S., NeuroStar is indicated for the treatment of MDD in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan's national health insurance.
In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar System were 4.2 times more likely to achieve remission compared to patients receiving sham treatment (P = 0.02; odds ratio = 4.05).6 The most common side effect is pain or discomfort at or near the treatment site, which usually resolves within one week. It is contraindicated in people with non-removable conductive metal in or near the head.
NeuroStar® is a registered trademark of
Media Contact:
610-455-2779
mdominick@vaultcommunications.com
____________
1 https://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml, accessed
2 Kessler RC, et al. (2003), JAMA
3 Gaynes BN, et al. (2008),
4 Post A, et al. (2001),
5 Liston C, et al. (2014), Biol Psychiatry
6
Source: Neuronetics